ImmunityBio, Inc.
IBRX
$2.51
$0.041.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 21.03% | 501.41% | |||
| Total Other Revenue | 127.63% | 166.67% | |||
| Total Revenue | 23.68% | 483.19% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 23.68% | 483.19% | |||
| SG&A Expenses | 16.29% | -26.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.89% | -13.97% | |||
| Operating Income | 13.52% | 19.21% | |||
| Income Before Tax | 30.99% | 36.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 30.99% | 36.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -26.09% | 15.00% | |||
| Net Income | 30.99% | 36.29% | |||
| EBIT | 13.52% | 19.21% | |||
| EBITDA | 13.90% | 20.15% | |||
| EPS Basic | 34.50% | 37.11% | |||
| Normalized Basic EPS | 35.19% | 37.09% | |||
| EPS Diluted | 35.03% | 28.20% | |||
| Normalized Diluted EPS | 35.16% | 37.25% | |||
| Average Basic Shares Outstanding | 5.36% | 1.30% | |||
| Average Diluted Shares Outstanding | 5.24% | 1.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||